STOCK TITAN

Amneal Pharmaceuticals, Inc. - AMRX STOCK NEWS

Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a leading global pharmaceutical company headquartered in Bridgewater, NJ. Amneal develops, manufactures, and distributes a diverse portfolio of over 280 generic and specialty pharmaceutical products across the United States, India, and Ireland. With a commitment to providing affordable medicines, Amneal operates through three key segments: Generics, Specialty, and AvKARE.

Generics Segment: This segment focuses on producing a wide range of dosage forms and delivery systems, including injectables and biosimilars, contributing significantly to the company's revenue. The Generics segment is dedicated to expanding across complex product categories and therapeutic areas, ensuring patients have access to vital medications.

Specialty Segment: Amneal's Specialty segment promotes proprietary branded pharmaceuticals targeting central nervous system and endocrine disorders. The segment has a growing portfolio of branded pharmaceuticals with a pipeline focused on addressing unmet medical needs, demonstrating the company's commitment to innovation.

AvKARE Segment: This segment distributes pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution. AvKARE focuses on offering consistent care and pricing to qualified entities, enhancing access to essential medicines for governmental and institutional markets.

Recently, Amneal has achieved significant milestones, including the resubmission of a Complete Response to the FDA for IPX203, an oral formulation for Parkinson’s disease, and entering a licensing agreement with Zambon Biotech for IPX203 in Europe. The company also launched PEMRYDI RTU®, the first ready-to-use version of pemetrexed for injection, underscoring their commitment to oncology treatment advancements.

Amneal's financial performance remains robust, with net revenue of $2.39 billion in 2023 and a strategic focus on expanding its reach through innovative products and international partnerships. The company continuously invests in research and development to meet the growing demands for affordable and high-quality medications, solidifying its position as a key player in the pharmaceutical industry. For more information, please visit www.amneal.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
Rhea-AI Summary

Amneal Pharmaceuticals (NYSE: AMRX) will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023. Co-CEO Chirag Patel and CFO Tasos Konidaris will represent the company. Mr. Patel will also host a fireside chat at 11:45 AM ET. Investors can access a live webcast from the Investor Relations section of Amneal's website, with a replay available for 90 days post-event.

Amneal is based in Bridgewater, NJ, and focuses on developing, manufacturing, and distributing around 270 generic and specialty pharmaceuticals in the U.S. The company is expanding its Generics segment with complex products and has a robust portfolio in Specialty pharmaceuticals aimed at addressing unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.32%
Tags
conferences

FAQ

What is the current stock price of Amneal Pharmaceuticals (AMRX)?

The current stock price of Amneal Pharmaceuticals (AMRX) is $7.78 as of December 20, 2024.

What is the market cap of Amneal Pharmaceuticals (AMRX)?

The market cap of Amneal Pharmaceuticals (AMRX) is approximately 2.4B.

What does Amneal Pharmaceuticals, Inc. specialize in?

Amneal Pharmaceuticals specializes in developing, manufacturing, and distributing a wide range of generic and specialty pharmaceutical products.

What are the key segments of Amneal Pharmaceuticals?

Amneal operates through three segments: Generics, Specialty, and AvKARE. The Generics segment focuses on a broad range of dosage forms and delivery systems, Specialty targets central nervous system and endocrine disorders, and AvKARE distributes pharmaceuticals to governmental agencies.

Where is Amneal Pharmaceuticals headquartered?

Amneal Pharmaceuticals is headquartered in Bridgewater, NJ, USA.

What recent product has Amneal Pharmaceuticals launched in the oncology space?

Amneal recently launched PEMRYDI RTU®, the first ready-to-use version of pemetrexed for injection, catering to oncology treatments.

What is the significance of Amneal's IPX203?

IPX203 is a novel oral formulation for the treatment of Parkinson’s disease. Amneal has resubmitted a Complete Response to the FDA and entered a licensing agreement with Zambon Biotech for its commercialization in Europe.

How does Amneal Pharmaceuticals contribute to the U.S. pharmaceutical market?

Amneal contributes by addressing chronic market shortages, particularly in the injectables category, and providing high-quality, affordable medicines through its expanded manufacturing capabilities.

What financial performance did Amneal achieve in 2023?

In 2023, Amneal reported a net revenue of $2.39 billion and continues to show robust financial health and growth prospects.

How is Amneal addressing the opioid crisis?

Amneal launched an Over the Counter Naloxone Hydrochloride Nasal Spray to help treat opioid overdoses, significantly expanding access to life-saving medication.

What are some key partnerships of Amneal Pharmaceuticals?

Amneal has partnered with Zambon Biotech for the commercialization of IPX203 in Europe and has also entered a distribution agreement with California for the supply of Naloxone HCI Nasal Spray.

How can investors get more information about Amneal Pharmaceuticals?

Investors can visit Amneal’s official website at www.amneal.com for detailed information and latest updates.

Amneal Pharmaceuticals, Inc.

NYSE:AMRX

AMRX Rankings

AMRX Stock Data

2.40B
135.66M
52.19%
46.48%
1.45%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
Bridgewater